interest in new york, page-31

Welcome to the PRR rollercoaster, Mrs P.
By long term plans, do you mean what else is on the cards if CVac is commercialised?

The ICS data about to be released with the interim CAN-003 data will go someway to inform the next steps.
If the method of action for CVac is confirmed, then Prima will look at other indications for CVac (other cancers that over express in MUC-1).
Theoretically, the path from development to approval should be shorter if the CANVAS trial is a success. But still some years away. In the meantime, CVac for ovarian cancer is the main focus.

There is information about this and their development of oral Gardasil (HPV) vaccine on their website.

As to when we're likely to see approval and commercialisation, there are a few views (Check the various coverage reports). But since CVac has been granted orphan drug status, and the FDA have introduced fast track approvals for drugs just like CVac, it should be sooner than it would otherwise be.
CANVAS trial is "due" for completion end of 2015, recruitment willing.
FDA "tries" to review priority trials within 6 months after receiving an application.
Not sure how the new Fast Track process will affect these timelines.